Estômago Guidelines

HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma

Escrito por Carla Brito Lopes

The College of American Pathologists (CAP), the AMERICAN SOCIETY FOR CLINICAL PATHOLOGY (ASCP), and the AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) collaborated to develop a clinical practice guideline that addresses appropriate testing of HER2/neu status in patients with gastric and gastroesophageal (GEA) cancers.

Titled “CAP-ASCP-ASCO HER2 TESTING AND CLINICAL DECISION MAKING IN GASTROESOPHAGEAL ADENOCARCINOMA GUIDELINE,” this evidence-based guidance is now available as an early online release published in Archives of Pathology & Laboratory Medicine, American Journal of Clinical Pathology, and the Journal of Clinical Oncology.

The overarching questions that the guideline development panel of experts addressed were:

  1. What is the optimal testing algorithm to assess HER2 status in patients with GEA?
  2. What strategies can help ensure optimal performance, interpretation, and reporting of established assays in patients with GEA?

Descarregar guideline aqui


Fontes:

1 – Angela N. Bartley, Mary Kay Washington, Christina B. Ventura, Nofisat Ismaila, Carol Colasacco, Al B. Benson III, Alfredo Carrato, Margaret L. Gulley, Dhanpat Jain, Sanjay Kakar, Helen J. Mackay, Catherine Streutker, Laura Tang, Megan Troxell, and Jaffer A. Ajani(2016) HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. Archives of Pathology & Laboratory Medicine: December 2016, Vol. 140, No. 12, pp. 1345-1363.

Sobre o autor

Carla Brito Lopes

Carla nasceu em Viana do Castelo em 1977. Licenciada em Anatomia Patológica, Citológica e Tanatológica pela Escola Superior de Tecnologia da Saúde em Lisboa. Concluiu a certificação em Laboratory Management pela ASCP (American Association of Clinical Pathology) em Setembro de 2016. Mestre em Genética Molecular e Biomedicina pela Faculdade de Ciências e Tecnologia da Universidade Nova de Lisboa. Trabalhou no Centro Hospitalar Lisboa Central entre 1998 e 2015, exercendo histopatologia e imunohistoquímica, sendo co-responsável pelo sector. Trabalha no Dr. Joaquim Chaves, Laboratório de Anatomia Patológica desde 2004 onde exerce funções de Coordenação Técnica e da Qualidade.

Deixe um comentário.